Correlations between the polymorphism of +869T/C in TGF-β1 and rheumatoid arthritis
- PMID: 30839312
- PMCID: PMC6454251
Correlations between the polymorphism of +869T/C in TGF-β1 and rheumatoid arthritis
Abstract
Objective: To explore the correlations between the polymorphism of the gene first exon +869T/C in transforming growth factor-β1 (TGF-β1) and rheumatoid arthritis (RA).
Methods: The patient group included 150 RA patients at the Department of Rheumatology in the First Affiliated Hospital of Chengdu Medical College between March 2014 and May 2017 and 150 healthy cases as the control group. The polymorphism was analyzed using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) and relationships between RA patients and genotypes were analyzed using logistic regression.
Results: The genotype frequency distribution and the genotype frequency of +869T/C locus was statistically different between two groups (P<0.05). Compared to the control group, the genotype frequency of +869 CC in the inpatient group was significantly lower (17.3% vs 32.7%), while the genotype frequency of +869 TT increased significantly (29.3% vs 20.7%). The T allele frequency in inpatient group was significantly higher than that in control group (57.83% vs 48.82%), while the C allele frequency in control group was significantly higher than that in inpatient group (51.18% vs 42.17%).
Conclusion: The polymorphism of the gene first exon +869T/C in TGF-β1 significantly correlated with RA and CC genotype might be the susceptible gene of RA.
Conflict of interest statement
The authors have no conflict of interest.
Similar articles
-
The association of transforming growth factor beta 1 gene polymorphisms with arthritis: a systematic review and meta-analysis.Clin Exp Med. 2021 May;21(2):331-340. doi: 10.1007/s10238-020-00678-5. Epub 2021 Jan 8. Clin Exp Med. 2021. PMID: 33417083
-
Study of transforming growth factor beta 1 gene +869T/C polymorphism in Egyptian rheumatoid arthritis patients and its relation to disease activity.Egypt J Immunol. 2022 Jan;29(1):19-28. Egypt J Immunol. 2022. PMID: 35171544
-
Interaction between TGF-β1 (869C/T) polymorphism and biochemical risk factor for prediction of disease progression in rheumatoid arthritis.Gene. 2014 Feb 25;536(2):393-7. doi: 10.1016/j.gene.2013.11.042. Epub 2013 Dec 4. Gene. 2014. PMID: 24315820
-
Transforming growth factor-beta1 869T/C, but not interleukin-6 -174G/C, polymorphism associates with hypertension in rheumatoid arthritis.Rheumatology (Oxford). 2009 Feb;48(2):113-8. doi: 10.1093/rheumatology/ken443. Epub 2008 Dec 23. Rheumatology (Oxford). 2009. PMID: 19106168
-
TGF-β1 +869T/C (rs1982073) gene polymorphism and susceptibility to rheumatoid arthritis: Updated systematic review and meta-analysis.Eur J Intern Med. 2021 May;87:66-74. doi: 10.1016/j.ejim.2021.02.010. Epub 2021 Feb 23. Eur J Intern Med. 2021. PMID: 33632596
Cited by
-
TGFB1 (rs1800470 and rs1800469) variants are independently associated with disease activity and autoantibodies in rheumatoid arthritis patients.Clin Exp Med. 2022 Feb;22(1):37-45. doi: 10.1007/s10238-021-00725-9. Epub 2021 May 27. Clin Exp Med. 2022. PMID: 34046752
-
The advances of methotrexate resistance in rheumatoid arthritis.Inflammopharmacology. 2020 Oct;28(5):1183-1193. doi: 10.1007/s10787-020-00741-3. Epub 2020 Aug 5. Inflammopharmacology. 2020. PMID: 32757110 Review.
-
Comprehensive systematic review and meta-analysis of the TGF-β1 T869C gene polymorphism and autoimmune disease susceptibility.Front Genet. 2025 Feb 20;16:1502921. doi: 10.3389/fgene.2025.1502921. eCollection 2025. Front Genet. 2025. PMID: 40051699 Free PMC article.
-
The association of transforming growth factor beta 1 gene polymorphisms with arthritis: a systematic review and meta-analysis.Clin Exp Med. 2021 May;21(2):331-340. doi: 10.1007/s10238-020-00678-5. Epub 2021 Jan 8. Clin Exp Med. 2021. PMID: 33417083
References
-
- McInnes IB, Schett G. Pathogenetic insights from the treatment of rheumatoid arthritis. The Lancet. 2017;389(10086):2328–2337. - PubMed
-
- Smolen JS, Landewé R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs:2016 update. Annals of the rheumatic diseases. 2017 annrheumdis-2016-210715. - PubMed